Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. - Wikidata - wikimedia - TriplyDB

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

http://www.wikidata.org/entity/Q42211373

about

Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.A general chemical synthesis platform for crosslinking multivalent single chain variable fragments.Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.Optimization of the crystallizability of a single-chain antibody fragment.Enhanced Bioactivity of the Anti-LOX-1 scFv Engineered by Multimerization Strategy.Non-Antibody Scaffolds as Alternative Therapeutic Agents A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system

P2860

Q33966998-13E97DEF-DA6F-4DBF-9518-60A21F529243 Q34503084-03492545-4D2F-4817-878E-994476E27F29 Q35835544-58413AE7-0BAF-4139-A236-4140649C94B0 Q36953914-9E825081-113E-4D84-B089-2FB07B7BCEEB Q37146338-C503A721-FCA6-4646-ABBC-069A57510A2B Q37698916-5EDFC9EA-7BBF-4C1F-9C33-CE09C2934E7C Q38885212-274C9BD6-B4B8-47A5-9F09-AF1D1F694E51 Q39119871-EAF00658-F8BA-475C-9612-50838FB96181 Q40482466-E2104B51-D1DA-4FAE-83E0-0237618405BB Q41718438-14F4C6C4-B946-47B7-9F91-9F3E1C6B3952 Q47362764-07899095-080B-410C-B0C7-8D926A6A263D Q57260221-EC2E30D8-AB92-49AA-B415-CC9F6F5FFAF3 Q58755125-70B819F8-A538-4EBD-BEBD-22E0523B50C8

P2860

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

http://www.wikidata.org/entity/Q42211373

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Noncovalent scFv multimers of tumor-targeting anti-Lewis

@nl

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

@en

type

label

Noncovalent scFv multimers of tumor-targeting anti-Lewis

@nl

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

@en

prefLabel

Noncovalent scFv multimers of tumor-targeting anti-Lewis

@nl

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

@en

P1433

Q42211373-6F3B48E9-F535-44C6-9705-F9D6B635CD47

P1476

Q42211373-04A42C16-EE28-44FD-A389-B712EA977475

P2093

Q42211373-1E781C8C-F81E-4E0B-A766-D868BACABEFD

Q42211373-370AA304-AB3A-4A07-A5C3-DD80C5BE05D8

Q42211373-41EE0060-C137-438D-BB80-BD668B0F7CE3

Q42211373-7194C740-8EB2-44CC-85D3-F1F2DD7E8779

Q42211373-724A71ED-C3A6-46EF-A331-B42DBE7CCA38

Q42211373-A110A2E9-25BC-4BF7-8C50-7E23AF5A93A1

Q42211373-A39A00CE-8514-47B7-B27D-F703EC4DA41B

Q42211373-A7711AAB-8CFF-421C-A374-E102FB13A3C1

Q42211373-AE359CF2-B31D-4443-9B9D-DE3F8C41193D

Q42211373-E0B1291C-E47C-4D7F-A52C-D142669BC157

P2860

Q42211373-2A82D5BA-C7BC-4D74-98DE-0A72BE54A499

Q42211373-2EAACFDE-BF50-43D8-9743-3D55B53FF8EA

Q42211373-33CF520B-887A-4857-B17B-6D019CCC1DC0

Q42211373-3B076F85-1CF7-456C-A18F-CAB6A22ABE9E

Q42211373-3D8C2225-3136-4848-96B7-A75B43F798A0

Q42211373-48C6B9E9-3C5F-4949-997B-B16BDD4253B5

Q42211373-4B08BDFF-8964-4E7F-BFEB-5B45022CB204

Q42211373-4F51CD0A-AAB1-458B-AFF2-9841CD2A6B80

Q42211373-5390093A-3813-4250-A701-56F6C2D8908F

Q42211373-5705546E-D92A-4797-9823-E8E61562FD48

P304

Q42211373-4500C489-D9E4-4AD2-9B74-B71CC3BF22CE

P31

Q42211373-57F8DC63-D93B-4643-AEE7-CACDDAC97061

P356

Q42211373-419F991C-2E7A-42C7-9809-7835443B2D49

P433

Q42211373-781D4E33-3264-40AB-8D3D-5599DE423AB1

P478

Q42211373-68818553-9366-4610-817E-998664C80F7A

P577

Q42211373-FABDB63E-A1E9-4E1A-AF0C-803CB15EA923

P5875

Q42211373-6749AE60-9E07-4D6D-80FD-6D58273A50C5

P698

Q42211373-5FE18414-41A0-4E9D-856C-535005E38635

P932

Q42211373-06BBF179-A4DD-4787-ADCB-E81E933C9CBF

P356

P1433

Protein Science

P1476

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

@en

P2093

Alexander A Kortt

http://www.w3.org/2001/XMLSchema#string

Andrew M Scott

http://www.w3.org/2001/XMLSchema#string

Ann M Bayly

http://www.w3.org/2001/XMLSchema#string

Barbara E Power

http://www.w3.org/2001/XMLSchema#string

Deborah R Shapira

http://www.w3.org/2001/XMLSchema#string

Joanne M Caine

http://www.w3.org/2001/XMLSchema#string

John E Burns

http://www.w3.org/2001/XMLSchema#string

Larissa Doughty

http://www.w3.org/2001/XMLSchema#string

Peter J Hudson

http://www.w3.org/2001/XMLSchema#string

Zhanqi Liu

http://www.w3.org/2001/XMLSchema#string

P2860

"Diabodies": small bivalent and bispecific antibody fragments

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3

Calculation of protein extinction coefficients from amino acid sequence data

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies.

Generating improved single-chain Fv molecules for tumor targeting.

ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding.

Tumor therapy with targeted atomic nanogenerators.

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

P304

734-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1110/PS.0228503

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10845909

http://www.w3.org/2001/XMLSchema#string

P698

12649432

http://www.w3.org/2001/XMLSchema#string

P932

2323837

http://www.w3.org/2001/XMLSchema#string